Gilteritinib Fumarate Patent Expiration
Gilteritinib Fumarate is Used for treating acute myeloid leukemia. It was first introduced by Astellas Pharma Us Inc
Gilteritinib Fumarate Patents
Given below is the list of patents protecting Gilteritinib Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xospata | US10786500 | Stable pharmaceutical composition for oral administration | Jul 01, 2036 | Astellas |
| Xospata | US11938130 | Stable pharmaceutical composition for oral administration | Jul 01, 2036 | Astellas |
| Xospata | US11938131 | Stable pharmaceutical composition for oral administration | Jul 01, 2036 | Astellas |
| Xospata | US11938132 | Stable pharmaceutical composition for oral administration | Jul 01, 2036 | Astellas |
| Xospata | US11938133 | Stable pharmaceutical composition for oral administration | Jul 01, 2036 | Astellas |
| Xospata | US11944620 | Stable pharmaceutical composition for oral administration | Jul 01, 2036 | Astellas |
| Xospata | US8969336 | Diamino heterocyclic carboxamide compound | Nov 28, 2032 | Astellas |
| Xospata | US9487491 | Diamino heterocyclic carboxamide compound | Jul 28, 2030 | Astellas |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Gilteritinib Fumarate's patents.
Latest Legal Activities on Gilteritinib Fumarate's Patents
Given below is the list recent legal activities going on the following patents of Gilteritinib Fumarate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Apr, 2024 | US9487491 |
| Patent Issue Date Used in PTA Calculation Critical | 02 Apr, 2024 | US11944620 |
| Patent eGrant Notification | 02 Apr, 2024 | US11944620 |
| Recordation of Patent eGrant | 02 Apr, 2024 | US11944620 |
| Recordation of Patent Grant Mailed Critical | 02 Apr, 2024 | US11944620 |
| Mail Patent eGrant Notification | 02 Apr, 2024 | US11944620 |
| Email Notification Critical | 02 Apr, 2024 | US11944620 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Mar, 2024 | US10786500 |
| Patent Issue Date Used in PTA Calculation Critical | 26 Mar, 2024 | US11938130 |
| Email Notification Critical | 26 Mar, 2024 | US11938130 |
Gilteritinib Fumarate's Family Patents
